CardioComm Solutions, Inc. (CardioComm Solutions) (TSX VENTURE: EKG)

today announced the launch of its new HeartCheck website

( This initiative

kicks off the company's 2012 Marketing Communications Campaign in

support of the their entry into the consumer, over-the-counter (OTC)

and prescribed Health Care Market and follows the recent Food and Drug

Administration (FDA) OTC clearance of the HeartCheck Pen Hand Held

ECG device.

"The launch of the HeartCheck website and co-sponsorship of the

CardioVascular Health insert for USA Today (February 23, 2102), are in

keeping with our commitment to enhance patient and consumer awareness

into cardiac arrhythmias and the risks associated with them. It also

highlights how ECG and heart rhythm monitoring can be of benefit in

primary and secondary disease prevention efforts" said Etienne Grima,

CEO of CardioComm Solutions.

The CardioVascular Health publication stresses the importance of open

patient-doctor dialogue and also addresses issues around Atrial

Fibrillation ("AF"). Within the publication, there is an information

segment "By The Numbers" authored by Dr. Anatoly Langer, Chairman of

the CardioComm Solutions Board of Directors, which provides statistics

for AF occurrence, the most common cardiac arrhythmia. The article

also describes the associated risk for stroke development and how to

best screen for AF.

"It has been a busy six weeks since the FDA clearance and we remain on

schedule in the introduction of the HeartCheck products and services.

The CardioVascular Health publication and the launching of our new

HeartCheck website are great opportunities to formally introduce the

HeartCheck PEN to the consumer audience" Grima added.

The HeartCheck website provides an overview of the HeartCheck

devices, reviews intended uses of each product and introduces the

GEMS Home application. This application enables Heart Rhythm (PEN)

and ECG recordings (ECG Monitor) to be sent to the CardioComm

Solutions' HeartCheck monitoring center - an extension to the

company's medical service called C4. This service will be launched

under the "HeartCheck Smart Monitoring" brand.

For a limited time, the website will provide an opportunity for

individuals to pre-register for a HeartCheck Pen in anticipation of

device sales later in the year. "There is a questionnaire which asks

the interested buyer for their email address, their city, as well as

optional information regarding their general health. With over 15

years of experience in providing medical solutions for ECG screening

and ECG management for hospitals, physicians and medical call centers,

we want to make this is more than a device launch. We want to

understand and best match the consumer's needs and leverage the

HeartCheck Pen's very real potential to make a positive impact on

quality of life, disease screening, and disease management of its

owners" said Grima.

"CardioComm Solutions intends to be a leading provider of ECG

Management Solutions. The new website, the soon to be launched

HeartCheck Smart Monitoring service and the information collected

from the pre-registration process will go a long way in tailoring

access to the devices and to bring more value to the telemedicine and

in-home monitoring market" noted Mr. Simi Grosman, member of

CardioComm Solutions' Board of Directors.

About CardioComm Solutions

CardioComm Solution's patented and proprietary technology is used in

products for recording, viewing, analyzing and storing

electrocardiograms (ECGs) for diagnosis and management of cardiac

patients. Products are sold worldwide through a combination of an

external distribution network and a North American-based sales team.

The company has earned the ISO 13485 certification, is HPB approved,

HIPAA compliant, and has received FDA market clearance for its

software devices. CardioComm Solutions, Inc. is headquartered in

Toronto, Canada, with offices in Victoria, B.C.

Forward-looking statements

This release may contain certain forward-looking statements with

respect to the financial condition, results of operations and business

of CardioComm Solutions and certain of the plans and objectives of

CardioComm Solutions with respect to these items. By their nature,

forward-looking statements involve risk and uncertainty because they

relate to events and depend on circumstances that will occur in the

future and there are many factors that could cause actual results and

developments to differ materially from those expressed or implied by

these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as

that term is defined in policies of the TSX Venture Exchange) accepts

responsibility for the adequacy or accuracy of this release.